Brain networks involved in essential tremor: elucidating tremor pathophysiology using EMG-fMRI

Completed

• Conditions: essential tremor; trembling; 10028037

• Registration Number: NL-OMON39415
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

Healthy subjects:
- subjectively healthy, including vision (after correction)
- 18 years or older and as well as possible age-matched with patients
- informed consent
- righthanded according to the Annett Handedness scale
ET patients:
- ET according to the cirteria defined by the Tremor Investigation Group
- using propranolol or primidone effectively (determined subjectively) and willing to stop this medication temporarily, or intention to start medication use
- heriditary ET
- informed consent
- 18 years or older
- righthanded acoording to the Annett Handedness scale
- subjectively healthy (except for tremor), including vision (after correction)

Exclusion Criteria

ET patients:
- absent (Tremor Rating Scale (TRS) Part A 2 UE < 2) or atypical tremor when off medication, as confirmed by polymyography (tremor recording)
- no measurable medication response
- no medication response after wash-in in de novo ET patients
General MR-related:
- presence of metal implants
- presence of electronic implants (eg heart pacemakers) en connections to electronic hardware (eg implanted electrodes)
- claustrophobia
- (possible) pregnancy
General other:
- MMSE < 27
- reumatoid disorder of the wrist, or other non-ET related disorders that can hamper fluent movement of the wrist
- use of medication/drugs that can influence taks performance

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main outcome measures: changes in patterns of BOLD-signal, coupled to changes<br /><br>in tremor intensity, extent of differentiated muscl use, and kinematic<br /><br>parameters such as reaction time, velocity and acceleration and the presence of<br /><br>'overshoot'. The different patient groups will be compared to each other and to<br /><br>a healthy control group.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>